Follow us on Twitter
twitter icon@FreshPatents


Immunotherapy patents

      

This page is updated frequently with new Immunotherapy-related patent applications.




 Method for generating t-cells compatible for allogenic transplantation patent thumbnailnew patent Method for generating t-cells compatible for allogenic transplantation
The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita.
Cellectis


 Claudin-6-specific immunoreceptors and t cell epitopes patent thumbnailnew patent Claudin-6-specific immunoreceptors and t cell epitopes
The present invention provides claudin-6-specific immunoreceptors (t cell receptors and artificial t cell receptors (chimeric antigen receptors; cars)) and t cell epitopes which are useful for immunotherapy.. .
Ganymed Pharmceuticals Ag


 Tc-ptp inhibitors as apc activators for immunotherapy patent thumbnailnew patent Tc-ptp inhibitors as apc activators for immunotherapy
The invention encompasses the novel class of compounds represented by the formula (i) below, which are inhibitors of the tc-ptp enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing tc-ptp mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases..
The Royal Institute For The Advancement Of Learning / Mcgill University


 Antibody-drug conjugates and uses thereof patent thumbnailnew patent Antibody-drug conjugates and uses thereof
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to trop-2 or ceacam5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg.
Immunomedics, Inc.


 Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents patent thumbnailnew patent Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents
Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness.
Best Pet Rx Ip, Inc. (50% Interest)


 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity patent thumbnailnew patent Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Immunomedics, Inc.


 Predicting response to epigenetic drug therapy patent thumbnailPredicting response to epigenetic drug therapy
The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy.
The Johns Hopkins University


 Method for reconstructing immune function using pluripotent stem cells patent thumbnailMethod for reconstructing immune function using pluripotent stem cells
According to the present invention, there are provided a method for producing a human t cell, which comprises the steps of inducing an ips cell from a human t cell, and differentiating the ips cell into a t cell; a pharmaceutical composition comprising the t cell produced by the method; and a method for cell-based immunotherapy using the method.. .
The University Of Tokyo


 Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy patent thumbnailPd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
Disclosed herein is a vaccine comprising an antigen and pd1 antibody and/or pdl1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject.
Inovio Pharmaceuticals, Inc.


 Novel methods of identifying patients responsive to immunotherapeutic strategies patent thumbnailNovel methods of identifying patients responsive to immunotherapeutic strategies
The invention includes a method of determining whether a mammal's cancerous tumor is associated with a hypermutator phenotype (i.e., harboring a large number of mutations) for the dna polymerase epsilon (pole) gene as compared to normal cells. The invention further includes a method of selecting patients harboring an immunogenic tumor that is responsive to immunotherapy..
Yale University


Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant cd8 t-cells

A previously unknown t cell receptor (tcr) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mtor inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative tcr activation pathway uniquely exists in a subset of cd8 t cells expanded in the setting of chronic rejection or rheumatoid arthritis.

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Method for emulsifying a triepitope peptide with montanide and kits for performing the same

The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and montanide as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.. .
Vaxon Biotech

Kidney-specific tumor vaccine directed against kidney tumor antigen g-250

This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California

Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof

Provided are novel human islet amyloid polypeptide, also known as amylin and iapp and proiapp respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for iapp and/or proiapp are also disclosed.
Neurimmune Holding Ag

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compounds and compositions for treating egfr expressing tumors

Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of egfr expressing tumors/cancers.
Shanghai Birdie Biotech, Inc.

Prostate-associated antigens and vaccine-based immunotherapy regimens

The present disclosure provides (a) isolated immunogenic paa polypeptides; (b) isolated nucleic acid molecules encoding immunogenic paa polypeptides; (c) vaccine compositions comprising an immunogenic paa polypeptide or an isolated nucleic acid molecule encoding an immunogenic paa polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.. .
Pfizer Inc

Method for repurposing ndc codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy

A method for adjudicating reimbursement for venom derived allergens between a pharmacist and a reimbursing entity comprises obtaining national drug codes (ndc's) for a plurality of venom derived allergens, storing in a central control database the obtained ndc's in association with an associated awp and associated information for the venom derived allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired ndc carrying venom derived antigen and a known dilution procedure how to translate back to the amount of base concentration of the ndc carrying venom derived antigen used to create the desired diluted level and number of doses, and determining if any of the ndc's in the central control database are contained within the third-party database and, if not, transferring the associated ndc's not in the third-party database to the third-party database.. .
Roca Medical Ltd.

Restricting nuclear protein to specific phases of the cell cycle

The present invention relates generally to mutagenesis of target genes that enhances the natural mutagenic capabilities of adaptive immune cells by providing a chimeric construct that exploits the ability of molecules such as aid to stimulate diversification and the ability of a second molecule to restrict nuclear activity of the molecules and/or protect cell viability. The invention provides a method for stimulating diversification in expressed genes, such as antibody genes, using polypeptides whose nuclear activity is restricted to specific phases of the cell cycle.
University Of Washington

Methods and compositions for treating solid tumors and enhancing tumor vaccines

The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of etrb, et-1, icam-1, or another protein found herein to play a role in homing of t cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of t cells to a solid tumor, or a nucleotide molecule encoding same..
The Trustees Of The University Of Pennsylvania

Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Hjurp peptides and vaccines including the same

Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic t cell inducibility of the original sequence.
Oncotherapy Science, Inc.

Vault immunotherapy

The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.. .
The Regents Of The University Of California

Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy

The present invention provides methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated oropharyngeal tumor or cancer, comprising the step of administering to a subject a recombinant listeria strain expressing a human papillomavirus antigen.. .
The Trustees Of The University Of Pennsylvania

Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)

A method of non-thermally ablating undesirable tissue in the body by application of pulsed, bipolar, instant charge reversal electrical fields of sufficient energy to cause complete and immediate cell membrane rupture and destruction. Energy is delivered through radio frequency pulses of particular frequencies, wave characteristics, pulse widths and pulse numbers, such that enhanced physical stresses are placed on the cell membrane to cause its immediate and complete destruction thereby spilling the entire cell content and membrane constituents into, the extracellular space without denaturing proteins so as to enable an immunological response to destroy and remove the target tissue and similarly marked tissue elsewhere in the subject..
Rfemb Holdings, Llc

Method of engineering chemotherapy drug resistant t-cells for immunotherapy

The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering allogeneic t-cell resistant to chemotherapeutic agents.
Cellectis

Lym-1 and lym-2 targeted car cell immunotherapy

Car cells targeting and antibodies human hla-dr are described as a new method of cancer treatment. It is proposed that hla-dr car cells are safe and effective in patients and can be used to treat human tumors expressing the hla-dr..

Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor

Provided are novel human-derived antibodies specific for transthyretin (ttr), preferably capable of binding misfolded, misassembled, and/or aggregated ttr species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with ttr amyloidosis are provided.
Neurimmune Holding Ag

Mimotopes for use in immunotherapy for shellfish and/or arthropod allergy

The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin met e 1.
The Chinese University Of Hong Kong

Novel immunotherapy against several tumors including neuronal and brain tumors

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Radio-imaging and radio-therapy of cancer using antibodies to haah

The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-haah antibodies for tumor imaging and immunotherapy are provided..
Panacea Pharmaceuticals Inc.

Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer

This invention relates to ly6g6f, vsig10, tmem25 and lsr proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble ly6g6f, vsig10, tmem25 and lsr molecules, extracellular domains of ly6g6f, vsig10, tmem25 and lsr and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
Compugen Ltd.

Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases

This invention relates to vstm5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.. .
Compugen Ltd.

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Granulysin in immunotherapy

Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kd granulysin thereby producing a monocyte-derived dendritic cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
Oncomed Pharmaceuticals, Inc.

Sirp polypeptide compositions and methods of use

Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. .
Ab Initio Biotherapeutics, Inc.

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Antigen-specific immunotherapy using tolerizing liposomes

The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
Pls-design Gmbh

Liposome-based immunotherapy

The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (ps) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided.
InstituciÓ Catalana De Recerca I Estudis AvanÇats



Immunotherapy topics:
  • Immunotherapy
  • Therapeutics
  • Antibodies
  • Immune Response
  • Monoclonal
  • Monoclonal Antibody
  • Stimulator
  • Immunostimulator
  • Compatibility
  • Histocompatibility
  • Specificity
  • Major Histocompatibility Complex
  • Radiation Therapy
  • Treatments
  • Amino Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.1909

    file did exist - 2524

    1 - 1 - 51